Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced that it has received a development milestone payment under its collaboration agreement with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Ra Pharma (RARX) PT Raised to $35 at SunTrust Robinson HumphreyDecember 10, 2018 12:35 PM Merck KGaA Reports FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract CancerDecember 10, 2018 10:10 AM Ra Pharmaceuticals (RARX) Reports Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia GravisDecember 10, 2018 7:01 AM Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with MerckDecember 6, 2018 7:30 AM